Lilly firms up case for Emgality in migraine market chaseEli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, Share XLilly firms up case for Emgality in migraine market chasehttps://pharmaphorum.com/news/lilly-firms-up-case-for-emgality-in-migraine-market-chase/
Lilly dips as biomed chief Christi Shaw heads to GileadChristi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job Share XLilly dips as biomed chief Christi Shaw heads to Gileadhttps://pharmaphorum.com/news/lilly-dips-as-biomed-chief-christi-shaw-heads-to-gilead/
Lilly’s migraine drug gets key cluster headache approvalThe FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving Share XLilly’s migraine drug gets key cluster headache approvalhttps://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/
Lilly claims fast FDA review for Emgality in cluster headacheEli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality Share XLilly claims fast FDA review for Emgality in cluster headachehttps://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/
Lilly joins CGRP race to cure migraineEli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the Share XLilly joins CGRP race to cure migrainehttps://pharmaphorum.com/news/lilly-joins-cgrp-race-to-cure-migraine/
